Scolr Pharma, Inc has entered into a licensing agreement with RedHill Biopharma Ltd an Israeli corporation, (RedHill), granting the latter the worldwide rights to market and sell ondansetron tablet formulations based on Scolr’s proprietary extended delivery technology (CDT). Ondansetron hydrochloride is the active ingredient in Zofran, GlaxoSmithKline’s drug to prevent chemotherapy and radiation related nausea and vomiting.

Under the terms of the Licensing Agreement, RedHill has agreed to make up front and additional payments to Scolr up to US$ 6 lakh based on achievement of certain regulatory milestones and the first commercial sale of the product and thereafter make payments to the company up to a maximum of US$ 30 million based on the aggregate net sales by RedHill of the licensed product over a ten year period.

Stephen J Turner, Scolr Pharma’s president and CEO, said, “We believe RedHill is a strong partner to collaborate with for the further development of our CDT-based ondansetron tablet formulations. As SCOLR continues to progress its pipeline of products, we will look for key strategic alliances, such as this licensing agreement with RedHill, to maximize the value of our pharmaceutical and nutritional product portfolio.”

Dror Ben-Asher, RedHill’s CEO, said, “CDT-based ondansetron is the latest addition to RedHill’s fast-growing pipeline of late clinical-stage drugs. We are excited about our partnership with SCOLR and intend to vigorously execute upon our development plans for CDT-based ondansetron.”

RedHill Biopharma is a pharmaceutical company focused primarily on acquisition and development of late clinical-stage new formulations of existing drugs.

Based in Bothell, Washington, Scolr Pharma, is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products.